100Table 56. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20141

Reasons therapy was extended

United States 825 70 (8.5) 153 (18.5) 86 (10.4) 11 (1.3) 341 Alabama 8 1 (12.5) 0 (0) 0 (0) 1 (12.5) 4 

Alaska 4 1 (25.0) 0 (0) 2 (50.0) 1 (25.0) 1 

Arizona 26 4 (15.4) 2 (7.7) 5 (19.2) 0 (0) 16 

Arkansas 13 0 (0) 2 (15.4) 4 (30.8) 2 (15.4) 3 

California 233 16 (6.9) 51 (21.9) 21 (9.0) 0 (0) 112 

Colorado 4 1 (25.0) 0 (0) 1 (25.0) 0 (0) 2 

Connecticut 5 0 (0) 1 (20.0) 0 (0) 0 (0) 3 Delaware 2 0 (0) 0 (0) 0 (0) 0 (0) 0 District of Columbia 3 0 (0) 1 (33.3) 0 (0) 0 (0) 2 

Florida 40 8 (20.0) 4 (10.0) 4 (10.0) 0 (0) 24 

Georgia 26 1 (3.8) 5 (19.2) 1 (3.8) 0 (0) 10 

Hawaii 2 1 (50.0) 0 (0) 0 (0) 0 (0) 0 

Idaho 1 1 (100.0) 0 (0) 0 (0) 0 (0) 0 

Illinois 30 1 (3.3) 4 (13.3) 3 (10.0) 0 (0) 14 

Indiana 11 2 (18.2) 0 (0) 1 (9.1) 0 (0) 7 

Iowa 3 0 (0) 0 (0) 0 (0) 0 (0) 0 

Kansas 3 1 (33.3) 1 (33.3) 0 (0) 0 (0) 1 

Kentucky 5 2 (40.0) 2 (40.0) 1 (20.0) 0 (0) 3 

Louisiana 17 0 (0) 4 (23.5) 1 (5.9) 2 (11.8) 1 

Maine 1 0 (0) 1 (100.0) 0 (0) 0 (0) 0 Maryland 21 1 (4.8) 5 (23.8) 5 (23.8) 0 (0) 4 

Massachusetts 30 2 (6.7) 3 (10.0) 0 (0) 0 (0) 10 

Michigan 2 0 (0) 1 (50.0) 0 (0) 0 (0) 1 

Minnesota 11 1 (9.1) 6 (54.5) 0 (0) 0 (0) 8 

Mississippi 7 0 (0) 0 (0) 0 (0) 1 (14.3) 0 

Missouri 3 0 (0) 0 (0) 0 (0) 0 (0) 0 Montana 0 0 ... 0 ... 0 ... 0 ... 0 Nebraska 1 0 (0) 1 (100.0) 1 (100.0) 0 (0) 0 

Nevada 4 0 (0) 4 (100.0) 0 (0) 0 (0) 0 

New Hampshire 0 0 ... 0 ... 0 ... 0 ... 0 New Jersey 28 4 (14.3) 7 (25.0) 2 (7.1) 0 (0) 10 

New Mexico 2 0 (0) 0 (0) 0 (0) 0 (0) 1 

Reporting area

Rifampin resistant Nonadherence Treatment failure Clinically in

No. (%)

Total cases 

with therapy 

extended2,3

Adverse event 

No. (%) No. (%) No. (%) No. 
101

1Most recent year for which data are available.2Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.3Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with the4Excludes New York City. 5Not included in U.S. totals.

Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.

New York State4 14 0 (0) 2 (14.3) 1 (7.1) 0 (0) 0 

New York City 28 3 (10.7) 7 (25.0) 5 (17.9) 2 (7.1) 3 

North Carolina 9 1 (11.1) 3 (33.3) 0 (0) 0 (0) 4 

North Dakota 4 1 (25.0) 0 (0) 0 (0) 0 (0) 3 

Ohio 14 1 (7.1) 5 (35.7) 3 (21.4) 0 (0) 5 

Oklahoma 4 0 (0) 1 (25.0) 0 (0) 0 (0) 2 

Oregon 3 1 (33.3) 2 (66.7) 0 (0) 0 (0) 0 

Pennsylvania 33 2 (6.1) 21 (63.6) 4 (12.1) 2 (6.1) 18 

Rhode Island 2 2 (100.0) 0 (0) 0 (0) 0 (0) 0 

South Carolina 2 0 (0) 0 (0) 0 (0) 0 (0) 1 

South Dakota 1 0 (0) 1 (100.0) 0 (0) 0 (0) 0 

Tennessee 8 1 (12.5) 1 (12.5) 2 (25.0) 0 (0) 3 

Texas 122 5 (4.1) 0 (0) 13 (10.7) 0 (0) 54 

Utah 1 0 (0) 0 (0) 0 (0) 0 (0) 1 

Vermont 0 0 ... 0 ... 0 ... 0 ... 0 Virginia 15 3 (20.0) 3 (20.0) 3 (20.0) 0 (0) 5 

Washington 12 1 (8.3) 0 (0) 3 (25.0) 0 (0) 1 

West Virginia 1 0 (0) 0 (0) 0 (0) 0 (0) 1 

Wisconsin 6 1 (16.7) 2 (33.3) 0 (0) 0 (0) 3 

Wyoming 0 0 ... 0 ... 0 ... 0 ... 0 

American Samoa5 0 0 ... 0 ... 0 ... 0 ... 0 

Fed. States of Micronesia5 1 0 (0) 0 (0) 0 (0) 0 (0) 0 

Guam5 1 0 (0) 0 (0) 0 (0) 0 (0) 0 Marshall Islands5 3 0 (0) 0 (0) 0 (0) 0 (0) 0 

N. Mariana Islands5 0 0 ... 0 ... 0 ... 0 ... 0 

Puerto Rico5 2 0 (0) 0 (0) 0 (0) 0 (0) 0 Republic of Palau5 1 0 (0) 0 (0) 0 (0) 0 (0) 0 

U.S. Virgin Islands5 0 0 ... 0 ... 0 ... 0 ... 0 

Table 56. (Con’t) Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20141

Reasons therapy was extended

Reporting area

Rifampin resistant Nonadherence Treatment failure Clinically in

No. (%)

Total cases 

with therapy 

extended2,3

Adverse event 

No. (%) No. (%) No. (%) No.